Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin
The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.
Abstract
This open‐label study investigated the effect of exenatide coadministration on the steady‐state plasma pharmacokinetics of digoxin. A total of 21 healthy male subjects received digoxin (day 1, 0.5 mg twice daily; days 2–12, 0.25 mg once daily) and exenatide (days 8–12, 10 μg twice daily). Digoxin plasma and urine concentrations were measured on days 7 and 12. Exenatide coadministration did not change the overall 24‐hour steady‐state digoxin exposure (AUC τ,ss) and C min,ss but caused a 17% decrease in mean plasma digoxin C max,ss (1.40 to 1.16 ng/mL) and an increase in digoxin t max,ss (median increase, 2.5 hours). Although the decrease in digoxin C max,ss was statistically significant, peak concentrations were within the therapeutic concentration range in all subjects. Digoxin urinary pharmacokinetic parameters were not altered. Gastrointestinal symptoms, the most common adverse effects of exenatide, decreased over time. Exenatide administration does not cause any changes in digoxin steady‐state pharmacokinetics that would be expected to have clinical sequelae; thus, dosage adjustment does not appear warranted, based on pharmacokinetic considerations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fair quality of methodology was considered in studies that enrolled only male subjects (“population” category) [14, 22, 25, 26, 28] or when blood sampling did not coincide with a steady state of an investigated drug [13–17, 19, 24].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [22]
In the citing paper
“All other GLP1 agonists resulted in a lower Cmax and a delayed tmax, but the AUC remained unaffected [15, 22, 32, 36].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [22]
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Thompson Coon, J. (2002) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2002.tb05480.x · Cited by 1,744
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Nausea that decreases over time has been the most commonly reported side effect in exenatide clinical trials.(2,3,4,11) Gradual dose escalation of exenatide has been demonstrated to reduce the proportion of subjects who experience nausea.”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 2×
“Nausea that decreases over time has been the most commonly reported side effect in exenatide clinical trials.(2,3,4,11) Gradual dose escalation of exenatide has been demonstrated to reduce the proportion of subjects who experience nausea.”
BackgroundMethodKolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552 · cited 3×
“A 5-day dosing regimen was chosen to assess the safety and tolerability of coadministration of exenatide and digoxin, because the common exenatide-related adverse effects, such as nausea, have been reported to manifest within the first week of exenatide dosing.(4,6,11) The dose regimen selected for digoxin was expecte…”
BackgroundMethodNielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457
Drugs as P-glycoprotein substrates, inhibitors, and inducers
Kim, R. B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001389 · Cited by 382 · cited 1×
“Digoxin is a P-glycoprotein substrate that reaches peak plasma concentrations 1 to 3 hours after oral administration, and it is mainly excreted unchanged in the urine (only 16% of a dose of digoxin is metabolized).(7,9) As digoxin has a narrow therapeutic window, change in steadystate plasma concentrations may result…”
BackgroundFineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353 · cited 2×
“Nausea that decreases over time has been the most commonly reported side effect in exenatide clinical trials.(2,3,4,11) Gradual dose escalation of exenatide has been demonstrated to reduce the proportion of subjects who experience nausea.”
BackgroundMethodFineman, M. S., Shen, L. Z., Taylor, K., Kim, D. D., & Baron, A. D. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.499 · Cited by 227 · cited 1×
“Gradual dose escalation of exenatide has been demonstrated to reduce the proportion of subjects who experience nausea.(13) No dose escalation of exenatide was performed during this study and may have contributed to the incidence of nausea reported during the study.”
Background
Research works printed but not linked: 2
- Kendall DM, 2004, Effects of exenatide (exendin‐4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea, Diabetologia, 47, A279
- 2003, Physician's Desk Reference, 1579
Cited by
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Advances in the Treatment of Type 2 Diabetes Mellitus
Israili, Z. H. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 165
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Metadata
- Authors
- Kothare, P. A., Soon, D. K. W., Linnebjerg, H., Park, S., Chan, C., Yeo, A., Lim, M., Mace, K. F., & Wise, S. D.
- Affiliations
- Eli Lilly (United States) (US)
- National University of Singapore (SG)
- Eli Lilly (United Kingdom) (GB)
- Corresponding author
- Kothare, Prajakti A.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-09
- Volume
- 45
- Issue
- 9
- Pages
- 1032-1037
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1976367840
- Cited by
- 69
- References
- 13
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2020: 1 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 4
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- exenatide, digoxin, drug-drug interactions, steady-state pharmacokinetics, Cmax, Tmax, urinary excretion, gastrointestinal adverse effects, dose adjustment, GLP-1 receptor agonists
- MeSH terms
- Exenatide, Adult, Anti-Arrhythmia Agents, Cardiotonic Agents, Digoxin, Drug Interactions, Humans, Male, Nausea, Peptides, Venoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin. https://app.cochat.ai/papers/10.1177/0091270005278806
- The paper
- Kothare, P. A., Soon, D. K. W., Linnebjerg, H., Park, S., Chan, C., Yeo, A., Lim, M., Mace, K. F., & Wise, S. D. (2005). Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270005278806
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.